IL‐6: Regulator of Treg/Th17 balance

By A. Kimura, T. Kishimoto. European Journal of Immunology, 2010

1,589 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system (2020, neutral): “IL-6 may also be responsible for the activation of T helper 17 (TH17) cells in the dendritic cell-T cell interaction [24].”
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. (2011, background): “In addition, IL-6 has been identified as major regulator of the balance between regulatory T cells (Treg) and effector Th17 cells [11].”
IL-6 in inflammation, immunity, and disease. (2014, background): “Up-regulation of the Th17/Treg balance is considered to be responsible for the disruption of immunological tolerance, and is thus pathologically involved in the development of autoimmune and chronic inflammatory diseases (Kimura and Kishimoto 2010).”
Cytokines in Radiobiological Responses: A Review (2012, positive): “Th17 cells have been implicated in the pathogenesis of many chronic inflammatory and autoimmune diseases (113) and they appear to be in a dynamic equilibrium with Tregs, as IL-6 can drive naive Tregs to become Th17 cells (114), a process that may be under HIF-1 control (115).”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “IL-6 was previously reported to block Treg cell activity and inhibit Treg generation induced by TGF-β; thus IL-6 is also considered as a regulator of Treg/Th17 balance (Kimura & Kishimoto, 2010).”